Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.37 |
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20058766 | 1.00 | DOT1L (0.37) | DOT1LPOLRMTMAP4K4ACVRL1STING1 | |
| SCHEMBL13696066 | 1.00 | DOT1L (0.37) | DOT1LPOLRMTMAP4K4ACVRL1STING1 | |
| SCHEMBL14642742 | 0.87 | POLRMT (0.39) | DOT1LPOLRMTMAP4K4ACVRL1STING1 | |
| SCHEMBL10154352 | 0.87 | POLRMT (0.39) | DOT1LPOLRMTMAP4K4ACVRL1STING1 | |
| SCHEMBL21120506 | 0.87 | POLRMT (0.39) | DOT1LPOLRMTMAP4K4ACVRL1STING1 | |
| SCHEMBL12388340 | 0.83 | EGFR (0.31) | — | |
| SCHEMBL25915354 | 0.82 | DOT1L (0.36) | DOT1LPOLRMTSTING1RIPK1 | |
| SCHEMBL24791068 | 0.82 | POLRMT (0.35) | DOT1LPOLRMTSTING1RIPK1 | |
| SCHEMBL14642541 | 0.81 | — | — | |
| SCHEMBL9912317 | 0.81 | DOT1L (0.35) | DOT1LPOLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | DOT1L 2852/4885POLRMT 62/4885MAP4K4 1849/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | DOT1L 3212/4885POLRMT 54/4885MAP4K4 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.